Recent updates to international and national clinical practice guidelines have reaffirmed the evidence-based role of topical nitroglycerin ointment in the management of hemorrhoidal disease—particularly for postoperative pain and acute thrombosed external hemorrhoids. The 2024 Clinical Practice Guidelines from the American Society of Colon and Rectal Surgeons (ASCRS), alongside key Chinese consensus statements—including the 2023 Expert Consensus on Perioperative Management of Hemorrhoids and the 2020 Expert Consensus on Day-Case Hemorrhoid Surgery—now uniformly endorse nitroglycerin ointment as a targeted, mechanism-specific adjunctive therapy.
Clinically, nitroglycerin ointment functions as a topical nitrate vasodilator that selectively relaxes the internal anal sphincter, thereby reducing spasticity-induced pain and improving local microcirculation. Unlike conventional hemorrhoidal preparations—which primarily aim to constrict vessels, reduce inflammation, or protect mucosa—nitroglycerin addresses the pathophysiologic core of post-hemorrhoidectomy pain: the vicious cycle of sphincter spasm, ischemia, and nociception. This distinct pharmacologic action fills a critical therapeutic gap in multimodal analgesia protocols, especially where opioid-sparing strategies are prioritized.
In surgical settings, nitroglycerin ointment is recommended as a cornerstone of perioperative pain control. When combined with warm sitz baths and oral analgesics, it significantly lowers visual analog scale (VAS) scores, accelerates return to normal bowel function and ambulation, and supports shorter hospital stays—making it particularly valuable in day-case and enhanced recovery after surgery (ERAS) pathways. According to the 2023 Chinese Expert Consensus, its use in hemorrhoidectomy patients carries Level 1 evidence and Grade A recommendation strength for managing both pain and sphincter spasm. Similarly, the 2020 Day-Case Surgery Consensus highlights its role in minimizing complications and facilitating early discharge.
In primary care and community settings, the ointment serves a vital bridging function. For patients presenting with acute thrombosed external hemorrhoids—who may lack immediate access to surgical intervention—topical nitroglycerin provides rapid symptomatic relief by reducing anal canal pressure and perianal edema. In select cases, this intervention can obviate the need for urgent excisional surgery altogether. The 2025 Integrated Traditional and Western Medicine Guideline for Hemorrhoids further classifies nitroglycerin ointment among “sphincter-spasm–relieving agents” and recommends its inclusion in multimodal regimens targeting VAS scores ≤4.
Internationally, the 2024 ASCRS Guidelines explicitly endorse nitroglycerin ointment for symptomatic relief of hemorrhoid-related pain and high-tone anal sphincter dysfunction. Importantly, the guideline underscores that it is an *adjunct*, not a substitute, for foundational interventions—including dietary fiber optimization, behavioral defecation training, and definitive surgical management when indicated. This alignment across geographies reflects growing global consensus on standardized, physiology-informed care.
Endorsement spans leading professional bodies: the World Federation of Chinese Medicine Societies’ Coloproctology Specialty Committee, the Chinese Society of Surgery’s Colorectal and Anal Surgery Group, the Beijing Society of Anorectal Diseases, the Chinese Association of Traditional Chinese Medicine, and the ASCRS—all recognize nitroglycerin ointment as a core component of evidence-based anorectal care.
Guideline-concordant use requires precise patient selection. Current evidence supports its application in three well-defined populations—accounting for an estimated 30–40% of all hemorrhoid cases: (1) patients experiencing significant pain and sphincter spasm following hemorrhoidectomy; (2) individuals with acute thrombosed external hemorrhoids; and (3) those with post-reduction pain after manual reduction of strangulated (incarcerated) hemorrhoids. This precision aligns with broader pharmaceutical goals of optimizing therapeutic index and minimizing off-label exposure.
Safety parameters are clearly delineated. Contraindications include hypersensitivity to nitrates, concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil), or systemic hypotension. Caution is advised in patients receiving antihypertensive agents due to potential additive blood pressure–lowering effects. These boundaries reflect adherence to national pharmacovigilance standards and reinforce the principle that effective symptom control must never compromise hemodynamic stability.
In summary, contemporary guidelines position topical nitroglycerin ointment not as a curative agent, but as a highly specific, physiology-targeted adjunct for symptomatic relief in defined hemorrhoidal scenarios. Its value lies in breaking the pain–spasm–ischemia cascade, enhancing patient comfort, and supporting efficient recovery—whether in ambulatory surgery centers, tertiary hospitals, or community clinics. Rigorous adherence to evidence-based indications, dosing, and contraindications remains essential to realizing its full clinical potential and upholding the highest standards of colorectal surgical care.